Last reviewed · How we verify
IlDong Pharmaceutical Co Ltd — Portfolio Competitive Intelligence Brief
3 marketed
0 filed
7 Phase 3
1 Phase 2
11 Phase 1
Live · 30-min refresh
Portfolio leaders (marketed + Phase 3 / filed)
| Drug | Generic | Phase | Class | Target | Area | First approval |
|---|---|---|---|---|---|---|
| V - C+V - C | V - C+V - C | marketed | Vitamin and mineral supplement | Nutritional supplementation | ||
| V - C - C+V | V - C - C+V | marketed | Inactivated viral vaccine | Immunology / Infectious Disease | ||
| Besifovir dipivoxil | Besifovir dipivoxil | marketed | Nucleotide reverse transcriptase inhibitor | Hepatitis B virus reverse transcriptase | Virology / Hepatology | |
| Placebo for Hydrochlorothiazide | Placebo for Hydrochlorothiazide | phase 3 | Cardiovascular | |||
| Placebo(for Rosuvastatin 20mg) | Placebo(for Rosuvastatin 20mg) | phase 3 | Cardiovascular | |||
| Placebo(for Rosuvastatin 10mg) | Placebo(for Rosuvastatin 10mg) | phase 3 | ||||
| Placebo for Tamsulosin | Placebo for Tamsulosin | phase 3 | Urology | |||
| Placebo(for Telmisartan 80mg) | Placebo(for Telmisartan 80mg) | phase 3 | Cardiovascular | |||
| Telmisartan/Amlodipine+Hydrochlorothiazide | Telmisartan/Amlodipine+Hydrochlorothiazide | phase 3 | Angiotensin II receptor antagonist, Calcium channel blocker, Thiazide diuretic | Angiotensin II receptor, L-type calcium channel | Cardiovascular | |
| Experimental drug | Experimental drug | phase 3 |
Therapeutic area mix
- Cardiovascular · 4
- Immunology / Infectious Disease · 1
- Nutritional supplementation · 1
- Urology · 1
- Virology / Hepatology · 1
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Competitive overlap (companies sharing drug classes)
- GlaxoSmithKline · 2 shared drug classes
- Merck Sharp & Dohme LLC · 2 shared drug classes
- Boryung Pharmaceutical Co., Ltd · 1 shared drug class
- Centers for Disease Control and Prevention · 1 shared drug class
- Chiang Mai University · 1 shared drug class
- Children's Hospital Medical Center, Cincinnati · 1 shared drug class
- China National Biotec Group Company Limited · 1 shared drug class
- Bristol-Myers Squibb · 1 shared drug class
Subscribe to ongoing alerts
Every new pipeline event for IlDong Pharmaceutical Co Ltd:
- IlDong Pharmaceutical Co Ltd pipeline updates — RSS
- IlDong Pharmaceutical Co Ltd pipeline updates — Atom
- IlDong Pharmaceutical Co Ltd pipeline updates — JSON
Cite this brief
Drug Landscape (2026). IlDong Pharmaceutical Co Ltd — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/ildong-pharmaceutical-co-ltd. Accessed 2026-05-16.